- Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland.
- Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients.
- Clinical programs planned to be included in the agreement span multiple solid tumor types, including lung, breast, and colorectal cancers.
KRAKOW, Poland, September 02, 2025 / Biotech Newswire / – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, is entering a strategic agreement with BioNTech to benefit Polish cancer patients by supporting trial site activation and patient recruitment for multiple investigational immunotherapies of BioNTech’s oncology pipeline in Poland.
The parties plan to leverage Ryvu’s operational excellence, expertise in oncology clinical operations, and existing trial site network to streamline access of Polish patients to BioNTech’s investigational immunotherapies. BioNTech intends to design and roll out clinical trials for some of the company’s priority programs in Poland and fund Ryvu’s services under the agreement. The clinical programs planned to be included in the agreement span multiple solid tumor types, including lung, breast, and colorectal cancer.
Kamil Sitarz, Chief Operating Officer, Management Board Member of Ryvu Therapeutics, said: "We are thrilled to build on our strong research relationship with BioNTech by entering a strategic agreement that leverages Ryvu’s operational excellence and expertise in oncology clinical operations to bring more BioNTech clinical programs to Poland. BioNTech’s science and innovation, combined with our shared ambition to bring innovative treatments to patients quickly, create a powerful momentum. We look forward to working together to streamline clinical trial activation and patient recruitment for BioNTech’s cancer immunotherapy clinical trials in Poland."
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel oncology therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules and antibody-drug conjugates directed at kinases, synthetic lethality, and immuno-oncology targets.
Ryvu’s most advanced program is RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies. RVU120 is currently in Phase II development (i) in combination with venetoclax for the treatment of patients with r/r AML – the RIVER-81 study, (ii) as a monotherapy for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) – the REMARK study, (iii) as a monotherapy and in combination with ruxolitinib for the treatment of patients with myelofibrosis (MF) – the POTAMI-61 study. Dapolsertib (MEN1703, SEL24) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is currently being investigated in a Phase II study in diffuse large B-cell lymphoma (DLBCL) – the JASPIS-01 study. RVU305, a potentially best-in-class, brain-permeable PRMT5 inhibitor aiming to treat multiple solid tumors, is currently in IND/CTA-enabling studies. Ryvu Therapeutics is also engaged in oncology collaborations with BioNTech and Exelixis.
Ryvu was founded in 2007 and is headquartered in Kraków, Poland. It is listed on the Warsaw Stock Exchange and is a component of the sWIG80 index.
Contact
Ryvu Therapeutics
Anna Wilk
+48 532 698 425
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Clinical Trials; Research Design; Patient Selection; Immunotherapy; Colorectal Neoplasms; Lung cancer; Breast cancer; Ryvu Therapeutics; BioNTech; strategic agreement; cancer immunotherapies; patient enrollment; oncology clinical programs; drug development; trial site network; patient recruitment; Kraków, Poland; Warsaw Stock Exchange
Source: Biotech Newswire